Current investigational drugs for major depression
- 9 May 2009
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 18 (6), 767-788
- https://doi.org/10.1517/13543780902880850
Abstract
Background: The World Health Organization (WHO) report has predicted that major depression will become a key cause of illness-induced disability by the year 2020, second only to ischemic heart diseases. Objectives/methods: Although a large number of antidepressant drugs (from monoamine oxidase inhibitors and tricyclic antidepressants to dual reuptake inhibitors) are available for treatment of the disease, approximately 30% of patients failed to respond to this therapy. Therefore, the search for newer or novel drug targets for the treatment of major depression continues. Some of these targets include dopamine, triple reuptake inhibition, L-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) pathway, sigma-1 receptors, neurosteroids, melatonin, glutamate, 5HT6, 5HT7 serotonin receptor antagonists, β-3 adrenoceptor antagonist, vasopressin V(Ib) receptor antagonists, NK2 tachykinin receptor antagonists, glucocorticoid receptor antagonists and corticotropin-releasing factor-1 receptor antagonists, as well as herbal antidepressant drugs. The present review attempts to discuss the status of some of these novel approaches and the drugs that are under investigation for the treatment of major depression. An attempt is also made to review the status of three indigenous plant-derived drugs, berberine, curcumin and rutin, as novel and safe future herbal antidepressants. Results/conclusion: There is an exciting future in the discovery of novel targets and target-specific agents for the management of major depression.Keywords
This publication has 100 references indexed in Scilit:
- Drug-Dependent Requirement of Hippocampal Neurogenesis in a Model of Depression and of Antidepressant ReversalBiological Psychiatry, 2008
- GABAAR Plasticity during Pregnancy: Relevance to Postpartum DepressionNeuron, 2008
- The 5-HT7 receptor influences stereotypic behavior in a model of obsessive-compulsive disorderNeuroscience Letters, 2007
- Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's diseaseMovement Disorders, 2006
- Pharmacological Profile of the “Triple” Monoamine Neurotransmitter Uptake Inhibitor, DOV 102,677Cellular and Molecular Neurobiology, 2006
- Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptakePsychopharmacology, 2006
- Effects of potassium channel inhibitors in the forced swimming test: Possible involvement of l-arginine-nitric oxide-soluble guanylate cyclase pathwayBehavioural Brain Research, 2005
- Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in ratsPharmacology Biochemistry and Behavior, 2005
- Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039Biochemical and Biophysical Research Communications, 2004
- Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535Synapse, 1998